Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment
Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of th...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Portuguese |
Published: |
Elsevier
2013-05-01
|
Series: | Jornal de Pediatria (Versão em Português) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2255553613000487 |
id |
doaj-a48102a9c55343fea334903481c8be4e |
---|---|
record_format |
Article |
spelling |
doaj-a48102a9c55343fea334903481c8be4e2020-11-24T23:56:45ZporElsevierJornal de Pediatria (Versão em Português)2255-55362013-05-0189322624210.1016/j.jpedp.2012.11.002Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatmentJoaquim E.B. Cabral0Jaques Belik1Neonatologista. Hospital São Luiz, São Paulo, SP, BrasilNeonatologista. Professor of Pediatrics and Physiology, University of Toronto, The Hospital for Sick Children, Toronto, CanadáObjectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical picture depends on the different factors involved, which are probably related to the etiology and physiopathological mechanisms. In addition to the measures used to allow the decrease in pulmonary vascular resistance after birth, some cases will require pulmonary vasodilators. Although nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. Conclusions: Despite recent technological advances and new physiopathological knowledge, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome.http://www.sciencedirect.com/science/article/pii/S2255553613000487Pulmonary hypertensionPulmonary vasodilatorsNitric oxide |
collection |
DOAJ |
language |
Portuguese |
format |
Article |
sources |
DOAJ |
author |
Joaquim E.B. Cabral Jaques Belik |
spellingShingle |
Joaquim E.B. Cabral Jaques Belik Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment Jornal de Pediatria (Versão em Português) Pulmonary hypertension Pulmonary vasodilators Nitric oxide |
author_facet |
Joaquim E.B. Cabral Jaques Belik |
author_sort |
Joaquim E.B. Cabral |
title |
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment |
title_short |
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment |
title_full |
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment |
title_fullStr |
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment |
title_full_unstemmed |
Persistent pulmonary hypertension of the newborn: Recent advances in pathophysiology and treatment |
title_sort |
persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment |
publisher |
Elsevier |
series |
Jornal de Pediatria (Versão em Português) |
issn |
2255-5536 |
publishDate |
2013-05-01 |
description |
Objectives: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments.
Data source: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011.
Data synthesis: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical picture depends on the different factors involved, which are probably related to the etiology and physiopathological mechanisms. In addition to the measures used to allow the decrease in pulmonary vascular resistance after birth, some cases will require pulmonary vasodilators. Although nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN.
Conclusions: Despite recent technological advances and new physiopathological knowledge, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome. |
topic |
Pulmonary hypertension Pulmonary vasodilators Nitric oxide |
url |
http://www.sciencedirect.com/science/article/pii/S2255553613000487 |
work_keys_str_mv |
AT joaquimebcabral persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment AT jaquesbelik persistentpulmonaryhypertensionofthenewbornrecentadvancesinpathophysiologyandtreatment |
_version_ |
1725456809701933056 |